WO2024131916 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13)
National phase entry:
Publication Number
WO/2024/131916
Publication Date
27.06.2024
International Application No.
PCT/CN2023/140803
International Filing Date
22.12.2023
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13)
[French]
COMPOSITIONS ET MÉTHODES POUR INHIBER L'EXPRESSION DE 17BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 13 (HSD17B13)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
Priority Data
PCT/CN2022/140956
22.12.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4511 | |
| EPO | Filing, Examination, Granting | 72650 | |
| Japan | Filing, Examination, Granting | 4224 | |
| South Korea | Filing, Examination, Granting | 6453 | |
| USA | Filing, Examination, Granting | 23240 |
Total:
111,078
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compositions and methods useful to reduce expression of 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) gene and for treatment of HSD 17B13-associated diseases and conditions are provided. Provided are HSD17B13 dsRNA agents, HSD17B13 antisense polynucleotide agents, compositions comprising HSD17B13 dsRNA agents, and compositions comprising HSD17B13 antisense polynucleotide agents that can be used to reduce HSD17B13 expression in cells and subjects.[French]
L'invention concerne des compositions et des méthodes utiles pour réduire l'expression du gène 17β-hydroxystéroïde déshydrogénase de type 13 (HSD17B13) et pour traiter des maladies et des états associés à HSD17B13. L'invention concerne également des agents d'ARNdb de HSD17B13, des agents polynucléotidiques antisens de HSD17B13, des compositions comprenant des agents d'ARNdb de HSD17B13 et des compositions comprenant des agents polynucléotidiques antisens de HSD17B13 qui peuvent être utilisés pour réduire l'expression de HSD17B13 dans des cellules et des sujets.